GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial.
OBJECTIVE
To assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.


METHODS
Single-center, randomized, single-blind, placebo-controlled trial.


METHODS
University-affiliated infertility clinic, between February 2005 and December 2007.


METHODS
Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.


METHODS
Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.


METHODS
Pregnancy rate was the primary outcome measure considered for assessing the role of triptorelin administration at the time of implantation. Clinical pregnancy, miscarriage, and ongoing pregnancy rates were the secondary outcome measures.


RESULTS
No differences were detected between the groups regarding clinical, seminal, or ovarian stimulation parameters. Pregnancy rate per randomized patient was similar in both groups (22.7% vs. 22.1%), as were clinical pregnancy, miscarriage, and ongoing pregnancy rates. There was a significant increase in the proportion of multiple pregnancies in the placebo group (10.3% vs. 36.8%).


CONCLUSIONS
Administration of GnRH agonist at the time of implantation does not improve the reproductive outcome of IUI cycles.
Bellver
José
J
Department of Reproduction, Instituto Valenciano de Infertilidad, University of Valencia, Valencia, Spain. jbellver@ivi.es
Labarta
Elena
E
Bosch
Ernesto
E
Melo
Marco A B
MA
Vidal
Carmina
C
Remohí
José
J
Pellicer
Antonio
A
D000328:Adult; D000465:Algorithms; D004334:Drug Administration Schedule; D010064:Embryo Implantation / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007315:Insemination, Artificial / Q000379:methods*; D008297:Male; D010919:Placebos; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D016037:Single-Blind Method; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage*; D014599:Uterus
D005300:Fertility Agents, Female; D010919:Placebos; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone